Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC)

被引：0
作者：
Lorenza, Rimassa [1 ]
Silvia, Bozzarelli [1 ]
Stefano, Cordio [2 ]
Filippo, Pietrantonio [3 ]
Laura, Toppo [4 ]
Sara, Lonardi [5 ]
Alberto, Zaniboni [6 ]
Roberto, Bordonaro [7 ]
Maria, Di Bartolomeo [8 ]
Wanda, Liguigli [4 ]
Vittorina, Zagonel [5 ]
Chiara, Tronconi Maria [1 ]
Luca, Di Tommaso [9 ]
Laura, Giordano [1 ]
Armando, Santoro [1 ]
机构：
[1] Ist Clin Humanitas IRCCS, Humanitas Canc Ctr, Rozzano, Italy
[2] Garibaldi Nesima Hosp, Dept Oncol, Catania, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[4] Ist Ospitalieri Cremona, Struttura Complessa Oncol, Cremona, Italy
[5] Ist Oncol Veneto IRCCS, Oncol Med 1, Padua, Italy
[6] Fdn Poliambulanza, Brescia, Italy
[7] Osped Garibaldi, Unita Oncol Med, Catania, Italy
[8] Fdn IRCCS Ist Nazl Tumori, Dept Oncol, Milan, Italy
[9] Ist Clin Humanitas IRCCS, Dept Pathol, Rozzano, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 028
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [33] Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
    Baljevic, Muhamed
    Zaman, Shadia
    Baladandayuthapani, Veerabhadran
    Lin, Yan Heather
    de Partovi, Claudia Morales
    Berkova, Zuzana
    Amini, Behrang
    Thomas, Sheeba K.
    Shah, Jatin J.
    Weber, Donna M.
    Fu, Min
    Cleeland, Charles S.
    Wang, Xin Shelley
    Stellrecht, Christine M.
    Davis, Richard E.
    Gandhi, Varsha
    Orlowski, Robert Z.
    ANNALS OF HEMATOLOGY, 2017, 96 (06) : 977 - 985
  • [34] Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
    Muhamed Baljevic
    Shadia Zaman
    Veerabhadran Baladandayuthapani
    Yan Heather Lin
    Claudia Morales de Partovi
    Zuzana Berkova
    Behrang Amini
    Sheeba K. Thomas
    Jatin J. Shah
    Donna M. Weber
    Min Fu
    Charles S. Cleeland
    Xin Shelley Wang
    Christine M. Stellrecht
    Richard E. Davis
    Varsha Gandhi
    Robert Z. Orlowski
    Annals of Hematology, 2017, 96 : 977 - 985
  • [35] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
  • [36] Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
    Chen, Yu
    Shi, Yi
    Lin, Jing
    Ye, Yun-bin
    Wang, Xiao-jie
    Chen, Gang
    Guo, Zeng-qing
    MEDICINE, 2015, 94 (40)
  • [37] Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Lee, Michael Sangmin
    Loehrer, Patrick J.
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen Keon
    Moore, Dominic T.
    Carlson, Cheryl Ann
    Sanoff, Hanna Kelly
    McRee, Autumn Jackson
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [38] Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).
    Kennecke, Hagen F.
    Chen, Leo
    Blanke, C. D.
    Cheung, Winson Y.
    Schaff, Kimberly
    Speers, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [39] Candidate genes associated with primary resistance to panitumumab (Pmab) in a phase II biomarker study of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Barry, G. S.
    Cheang, M. C.
    Leung, S.
    Zhou, C.
    Kennecke, H. F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S559 - S559
  • [40] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    Garrido-Laguna, I.
    McGregor, K. A.
    Wade, M.
    Weis, J.
    Gilcrease, W.
    Burr, L.
    Soldi, R.
    Jakubowski, L.
    Davidson, C.
    Morrell, G.
    Olpin, J. D.
    Boucher, K.
    Jones, D.
    Sharma, S.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1257 - 1264
12345